NATCO Pharma Q1 FY2024 Investor Presentation

NATCO Pharma Limited presents Q1 FY2024 results as a diversified pharmaceutical enterprise with strong oncology positioning in India and complex generics focus in US markets. The company operates across three regions (India, US, ROW) with 4,900 employees and reported total revenues of ₹28,117 million for FY2023, supported by market capitalization of USD 1.51 billion.